Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 5/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966888 | 0.89 | HDAC3 (0.53) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6465668 | 0.87 | MAPT (0.53) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6463219 | 0.84 | MMP12 (0.45) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6466773 | 0.84 | FFAR1 (0.46) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL4798497 | 0.81 | TDP1 (0.52) | SMN1; SMN2CNR2TSHR | |
| SCHEMBL3818361 | 0.80 | CPA1 (0.60) | MMP12MMP2MMP9KEAP1CPA1 | |
| SCHEMBL18065715 | 0.80 | MMP12 (0.56) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6462362 | 0.80 | CPA1 (0.60) | MMP12MMP2MMP9KEAP1CPA1 | |
| SCHEMBL6462808 | 0.80 | FFAR1 (0.50) | MMP12MMP13MMP2MMP9SMN1; SMN2 | |
| SCHEMBL29828305 | 0.80 | MAPT (0.58) | HDAC3HDAC4HDAC1SMN1; SMN2HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903233-B2 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-1344763-A1 | Process for producing optically active 3-halogenocarboxylic acid esters and 3-azide-carboxylic acid esters | Takasago International Corporation (JP) | 2003-09-17 | — | — | EP | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225301-A1 | Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester | HDHD5, APEH, AOC3 | MMP12 132/4885MMP13 49/4885MMP2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.